Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
Abstract Background Bloodstream infections (BSIs), or bacteremia, are responsible for considerable disease burden. Increasing rates of antibiotic resistance and delays in selection of appropriate treatment lead to increased morbidity, mortality, and costs. Due to limitations of current standard trea...
Main Authors: | Z. S. Khankhel, R. J. Dillon, M. Thosar, C. Bruno, L. Puzniak |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | Annals of Clinical Microbiology and Antimicrobials |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12941-022-00528-0 |
Similar Items
-
Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
by: Marco Fiore, et al.
Published: (2021-01-01) -
Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study
by: Hakeam A. Hakeam, et al.
Published: (2022-10-01) -
Real-world use of ceftolozane/tazobactam: a systematic literature review
by: Laura Puzniak, et al.
Published: (2021-04-01) -
Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020-01-01) -
Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
by: Emily Fox, et al.
Published: (2022-11-01)